Changes in Hong Kong stocks | Xiansheng Pharmaceutical (02096) rose more than 5% in early trading and will release mid-term results today, innovative drugs and BD revenue drive high performance growth

The Zhitong Finance App learned that Xiansheng Pharmaceutical (02096) rose more than 5% in early trading. As of press release, it had risen 4.27% to HK$12.69, with a turnover of HK$40.174 million.

According to the news, Xiansheng Pharmaceutical will hold a 2026 interim results conference on August 21. According to Xiansheng Pharmaceutical's announcement, revenue for the first half of the year is expected to reach 4.55 billion yuan to 4.61 billion yuan, up 26.9% to 28.6% year on year; profit to mother is expected to be 810 million yuan to 860 million yuan, up about 34.8% to 43.1% year on year; adjusted net profit to mother is expected to be 950 million yuan to 1 billion yuan, up about 46.5% to 54.2% year on year. This is mainly due to the increase in revenue from innovative drugs and external licensing revenue.

Huatai Securities believes that against the backdrop of large industry fluctuations in the second quarter, the company achieved performance that exceeded expectations, showing strong market demand for new varieties and efficiency improvements brought about by executive changes. Furthermore, the normalization of BD is also expected to bring about continued growth. It is expected that the company's endogenous business will maintain the forecast trend in the mid-report throughout the year, while profit side benefit BD will continue to increase by leaps and bounds. Maintain “buy-in.”